

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers are Required to Complete This Page 2, 54

1. Registrant Name Capitol Associates, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 426 C Street, NE, Washington, DC 20002			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Debra M. Hardy Havens	Telephone 202-544-1880	E-mail (optional) dh@capitolassociates.com	5. Senate ID # 8101-253
7. Client Name Cystic Fibrosis Foundation	<input type="checkbox"/> Self	6. House ID # 308130005	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date 10/31/00

11. No Lobbying Activity

**INCOME OR EXPENSES** - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ <u>\$ 20,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code</p>
---	---

Signature Debra M. Hardy Havens  
Printed Name and Title Debra M. Hardy Havens, CEO

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Funding for medical research.

H.R. 4577 and S. 2553 - Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2000. Title II - Secure support for the National Institutes of Health, relative to gene therapy and cystic fibrosis.

H.R. 4461 and S. 2536 - Making appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies programs for the fiscal year ending September 30, 2001, and for other purposes; Title VI - tracked, monitored, reported consideration of legislation for FDA Appropriations.

17. House(s) of Congress and Federal agencies contacted

Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 2 of 6

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- S. 573 - Medical Information Privacy and Security Act. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- S. 578 - Health Care PIN Act. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- S. 881 - Medical Information Protection Act of 1999. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- S. 1322/H.R. 2457 - Genetic Nondiscrimination in Health Insurance Protection Act of 1999. Tracked, monitored, and reported on consideration of legislation.
- H.R. 1057 - Medical Information Privacy and Security Act. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- H.R. 2404 - Personal Medical Information Protection Act of 1999 - Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- H.R. 2470 - Medical Information Protection and Research Enhancement Act of 1999. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- H.R. 1941 - Health Information Privacy Act. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- H.R. 2455 - Consumer Health and Research Technology (CHART) Protection Act. Tracked, monitored, and reported on provisions related to the conduct of medical research and informed consent.
- H.R. 10/ S. 900 - Financial Services Act of 1999 Title III, Subtitle D, The Confidentiality of Health and Medical Information. Opposed the inclusion of medical privacy provisions in this legislation
- Tracked and monitored rule-making process for medical records privacy.

17. House(s) of Congress and Federal agencies contacted

Check if None

House  
 Senate  
 Department of Health and Human Services  
 Environmental Protection Agency

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Debra M. Hardy Havens		<input type="checkbox"/>
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 3 of 6

Registrant Name Capitol Associates, Inc. Client Name Cystic Fibrosis Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Tracked and reported on Congressional Hearings on stem cell research.  
S. 2015 - Stem Cell Research Act of 2000. Tracked, monitored, and reported consideration of legislation.

Tracked and reported on Congressional Hearings and White House and DHHS oversight of gene therapy research and clinical research.

H.R. 1798: Clinical Research Enhancement Act of 1999

Met with sponsors of legislation to urge Committee and floor consideration of legislation. Tracked, monitored and reported consideration of legislation.

H.R. 2391, National Center for Research on Domestic Health Disparity Act -- tracked, monitored, reported consideration of legislation.

H.R. 2621, Pediatric Research Initiative Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 3110, Dr. Sydney E. Salmon Access to Cancer Research Clinical Trials Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 4605, Human Research Subjects Protections Act of 2000 -- tracked, monitored, reported consideration of legislation.

S. 1010, Medical Innovation Tax Credit for Clinical Testing Research -- tracked, monitored, reported consideration of legislation.

S. 1267, Clinical Trials Disclosure Act of 1999 -- tracked, monitored, reported consideration of legislation.

S. 1813, Clinical Research Enhancement Act of 1999 -- tracked, monitored, reported consideration of legislation.

S. 296 Federal Research Investment Act- A bill to ensure that Federal funding levels for fundamental, scientific, and pre-competitive engineering research increase to equal approximately 2.5 percent of the total annual Federal budget. Tracked, monitored, and reported, consideration and mark-up of legislation.

H.R. 2418, To amend the Public Health Services Act to revise and extend programs relating to organ procurement and transplantation - tracked, monitored, reported consideration of legislation.

H.R. 3242 and S. 1873, To delay the effective date of the final rule regarding the Organ Procurement and Transplantation Network - tracked, monitored, reported consideration of legislation.

17. House(s) of Congress and Federal agencies contacted

Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 4 of 6

Registrant Name Capitol Associates, Inc.

Client Name Cystic Fibrosis Foundation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying

on behalf of the client during the reporting period. Using a separate page for each issue, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

HR 1388, Medicare Cancer Clinical Trials Act of 1999 - a bill to reform managed care. Tracked, monitored, reported, and advocated for reimbursement for clinical trials.

S 784, Medicare Cancer Clinical Trials Act of 1999- a bill to reform managed care. Tracked, monitored, reported, and advocated for reimbursement for clinical trials.

Monitor and track medicare reforms, and prescription drug benefit.

HR 4680, Medicare Rx 2000 Act.

HR 4770, Medicare Guaranteed and Defined Rx Benefit and Health Provider Relief Act of 2000.

S. 2807, Medicare Prescription Drug & Modernization Act of 2000.

S. 2758, Medicare Outpatient Drug Act of 2000.

S. 2753, Medicare Expansion Plan

Tracked and monitored Executive Order on Clinical Trials and Medicare

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Debra M. Hardy Havens		<input type="checkbox"/>
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>
Matthew Williams		<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

**LOBBYING REGISTRATION ADDENDUM**  
Lobbying Disclosure Act of 1995 (Section 5)

Registrant Name Capitol Associates, Inc.

Client Name Cystic Fibrosis Foundation

Line #	Information to be included
15.	HCR
16.	Tracked, monitored, reported, and advocated for reimbursement for clinical trials and patient access to specialty care S. 1344 Patient's Bill of Rights Act of 1999 - a bill to reform managed care. HR 2990, Quality Care for the Uninsured Act of 1999. H.R. 2723, Patient Protection Bill/Bipartisan Consensus Managed Care Improvement Act of 1999. S. 2274, The Family Opportunity Act of 2000 - support passage. H.R. 4825, The Family Opportunity Act of 2000 - support passage. Met with the Environmental Protection Agency (EPA) to discuss toxicity of <i>B.Cepacia</i> on patients with Cystic Fibrosis.

Addendum